p******a
发帖数: 483 | |
r***o
发帖数: 162 | 2 no
the key reason why not so many new molecular entities are approved:
1. pharmas are not making any
2. FDA does not want to approve becuase its concern of liabilty
generic:
already very easy.
【在 p******a 的大作中提到】
: http://biz.yahoo.com/ap/090322/fda_drugmakers.html?sec=topStories&pos=2&asset=TBD&ccode=TBD
: FDA一拆二。一个管drug，一个管food。好像是要加快新药审批。这样会给制药行业和
: generic带来什么影响？
|
v*x
发帖数: 1370 | 3 maybe FDA would tolerate some risky drugs, a.k.a., a couple of deaths in the
Phase III trial won't blow up new drug any more.
【在 r***o 的大作中提到】
: no
: the key reason why not so many new molecular entities are approved:
: 1. pharmas are not making any
: 2. FDA does not want to approve becuase its concern of liabilty
: generic:
: already very easy.
|
p******a
发帖数: 483 | 4 你是说FDA降低标准，制药公司的春天要来了？
the
【在 v*x 的大作中提到】
: maybe FDA would tolerate some risky drugs, a.k.a., a couple of deaths in the
: Phase III trial won't blow up new drug any more.
|
r***o
发帖数: 162 | 5 That is not going to happen.
Nobody has the gut to approve anything that has clear safety concern. Of
course, there are always excptions, especially in the oncology area.
the
【在 v*x 的大作中提到】
: maybe FDA would tolerate some risky drugs, a.k.a., a couple of deaths in the
: Phase III trial won't blow up new drug any more.
|
